ZS Pharma readies NDA as competitor Relypsa's filing nears
This article was originally published in Scrip
ZS Pharma will seek US and EU approvals for its hyperkalemia drug ZS-9 (sodium zirconium cyclosilicate) in 2015 based on two sets of positive Phase III results, but Relypsa is ahead of the game with plans to submit a new drug application (NDA) to the US FDA this year for its competing therapy patiromer.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.